论文部分内容阅读
目的评价吉西他滨联合希罗达治疗晚期胰腺癌的临床疗效。方法选择我院2010年1月-2011年1月PS评分大于2分的38例晚期胰腺癌患者作为观察对象,对38例晚期胰腺癌的患者进行吉西他滨联合希罗达方案化疗3个周期。观察患者化疗后的疾病控制率、无进展生存期及化疗后的不良反应。结果本组研究的疾病控制率为53.57%,无进展生存期的中位时间12.5个月,不良反应主要是胃肠反应骨及髓抑制。结论吉西他滨联合希罗达化疗方案疾病控制率及临床收益率明显,且能显著提高患者的无进展生存期,不良反应少,可作为晚期胰腺癌治疗的新思路。
Objective To evaluate the clinical efficacy of gemcitabine combined with xeloda in the treatment of advanced pancreatic cancer. Methods 38 patients with advanced pancreatic cancer with PS score greater than 2 in our hospital from January 2010 to January 2011 were selected as observation objects. 38 patients with advanced pancreatic cancer were treated with gemcitabine plus Xeloda chemotherapy for 3 cycles. The patient’s disease control rate, progression-free survival, and adverse reactions after chemotherapy were observed. Results The disease control rate in this study was 53.57%, and the median progression-free survival time was 12.5 months. The adverse reactions were mainly gastrointestinal reactions and bone marrow inhibition. Conclusion The gemcitabine combined with Xeloda chemotherapy has obvious disease control rate and clinical benefit rate, and can significantly improve the patient’s progression-free survival with fewer adverse reactions. It can be used as a new idea for the treatment of advanced pancreatic cancer.